We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Mifinder is a support platform that connects people who have shared unique life experiences. Mifinder uses search filters and GPS to help users connect based on shared life experiences.
days to go: Expired investment: £19,095
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £144,265
WeddingPlanner.co.uk is the trading name of a disruptive technology company offering an online platform to simplify the complex and stressful process of wedding planning for Couples and Suppliers.
days to go: Expired investment: £92,322
Angels on the Park is a nursery opening in East London that provide flexible childcare, extended their operating hours and arrange babysitting in the family home. (EIS pending) (SEIS Pending)
days to go: Expired investment: £61,450
Roomfortea is a peer-to-peer platform matching guests and hosts globally for mid-term stays. They adapt the traditional concept of homestay to make co-living simple for a generation of young professionals wanting to live and work in cities around the world. 
days to go: Expired investment: £91,622
Bioepic is an app which enables users to easily and non-invasively measure their health status in just 30 seconds using just a smartphone. The app calculates pulse wave velocity, body temperature, blood pressure, heart rate variability chaos, vascular stiffness and the effectiveness of inhalers. 
days to go: Expired investment: £12,500
Actve is on a mission to build a platform that caters to the new wave of instructors, social media influencers and athletes becoming online content creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £166,670
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph